Guillermo Garcia-Manero, M.D.
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Guillermo Garcia-Manero, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:01 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06641414 · Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).Ascentage Pharma Group Inc. · recruiting · Higher-risk Myelodysplastic Syndrome · study chair
- Ph2NCT00903760 · Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)M.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome · principal investigator
- Ph2NCT00656617 · Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) · study chair
- Ph1/Ph2NCT00075010 · Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic SyndromesM.D. Anderson Cancer Center · completed · Leukemia, Myelodysplastic Syndromes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.